Ra Capital Management, a director and more than 10% owner of 89bio Inc. (ETNB), bought common stock worth $49.99 million last ...

SG Americas Securities LLC lifted its holdings in 89bio, Inc. (NASDAQ:ETNB – Free Report) by 18.3% during the fourth quarter, ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of 89bio (NasdaqGM:ETNB) with a Outperform ...

abrdn plc reduced its stake in 89bio, Inc. (NASDAQ:ETNB – Free Report) by 30.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC.The fund owned ...

(NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a new stock ...

Every investor in 89bio, Inc. (NASDAQ:ETNB) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 58% ownership. That is, ...

The offering of the securities was made only by means of a prospectus, including a prospectus supplement, forming a part of ...

Goldman Sachs & Co. LLC, Leerink Partners and BofA Securities are acting as lead book-running managers and Cantor is acting as book-running manager for the proposed offering.

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...